Dan Edelstein is the founder of Haystack Oncology. Haystack Oncology has raised $56M in total funding. Latest round: Series A. Based in Baltimore, MD, USA.
Dan Edelstein is the CEO and co-founder of Haystack Oncology, an oncology company focused on optimizing minimal residual disease (MRD) testing through next-generation circulating tumor DNA (ctDNA) detection technology. The company launched with a $56 million Series A financing round to develop and commercialize its personalized cancer diagnostic test. Haystack Oncology's technology aims to detect trace amounts of MRD post-initial cancer treatment to inform optimal therapy decisions.
Full founder directory · Investor directory · Company funding database · Fundraising library